Phynova Revenue and Competitors

Long Hanborough,

Location

N/A

Total Funding

Health

Industry

Estimated Revenue & Valuation

  • Phynova's estimated annual revenue is currently $4.2M per year.(i)
  • Phynova's estimated revenue per employee is $189,000

Employee Data

  • Phynova has 22 Employees.(i)
  • Phynova grew their employee count by 29% last year.

Phynova's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
VPReveal Email/Phone
3
Chief Marketing OfficerReveal Email/Phone
4
Chief Commercial OfficerReveal Email/Phone
5
Chief Financial OfficerReveal Email/Phone
6
Head Science & Regulatory Affairs, AmericasReveal Email/Phone
7
Head Science, AmericasReveal Email/Phone
8
VP Business DevelopmentReveal Email/Phone
9
VP Business DevelopmentReveal Email/Phone
10
Global Head ScienceReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$409M108215%N/AN/A
#2
$5.5M29-15%N/AN/A
#3
$31.3M116-13%N/AN/A
#4
$14.8M61-18%N/AN/A
#5
$13.1M548%N/AN/A
#6
$34.3M1274%N/AN/A
#7
$219.4M65017%N/AN/A
#8
$505.4M133722%N/AN/A
#9
$31.3M11627%N/AN/A
#10
$123.2M36513%N/AN/A
Add Company

What Is Phynova?

Phynova is an innovative life science company based in Oxford, United Kingdom. Phynova has developed all natural plant-derived actives for use as foods and consumer healthcare products. Phynova's product portfolio includes a functional ingredient Reducoseâ„¢ that promotes healthy blood glucose levels, Phynova Joint and Muscle Reliefâ„¢, an Over The Counter drug approved in the UK and Melokinexâ„¢, a pharmaceutical drug candidate for post-operative ileus.

keywords:N/A

N/A

Total Funding

22

Number of Employees

$4.2M

Revenue (est)

29%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Phynova News

2022-04-17 - Blood sugar support supplements become more versatile

Phynova's branded Reducose ingredient, a proprietary water extract of the plant Morus alba, is the hero ingredient in Nestlé Health Sciences'...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$115.8M34312%N/A